National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meetings, 10262 [2016-04236]
Download as PDF
<![CDATA[
10262
Federal Register / Vol. 81, No. 39 / Monday, February 29, 2016 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Heart, Lung, and
Blood Initial Review Group; Heart, Lung, and
Blood Program Project Review Committee.
Date: March 18, 2016.
Time: 8:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Jeffrey H. Hurst, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6701 Rockledge Drive, Room 7208, Bethesda,
MD 20892, 301–435–0303, hurstj@
nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: February 23, 2016.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–04233 Filed 2–26–16; 8:45 am]
BILLING CODE 4140–01–P
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
contract proposals discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Arthritis and
Musculoskeletal and Skin Diseases Initial
Review Group; Arthritis and Musculoskeletal
and Skin Diseases Clinical Trials Review
Committee; AMSC Clinical Review Meeting.
Date: March 15–16, 2016.
Time: March 15, 2016, 8:00 a.m. to 5:00
p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: Charles H. Washabaugh,
Ph.D., Scientific Review Officer, Scientific
Review Branch NIAMS/NIH, 6701
Democracy Boulevard, Suite 816, Bethesda,
MD 20892, 301–594–4952, washabac@
mail.nih.gov.
Name of Committee: National Institute of
Arthritis and Musculoskeletal and Skin
Diseases Special Emphasis Panel; Clinical
Studies Management.
Date: March 17, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health/
NIAMS, One Democracy Plaza, 6701
Democracy Boulevard, Bethesda, MD 20892.
Contact Person: Kathy ScD Salaita, Chief,
Scientific Review Branch, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3172,
MSC 7770, Bethesda, MD 20892, 301–806–
8250, salaitak@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.846, Arthritis,
Musculoskeletal and Skin Diseases Research,
National Institutes of Health, HHS)
Dated: February 23, 2016.
Sylvia Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–04236 Filed 2–26–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
asabaliauskas on DSK5VPTVN1PROD with NOTICES
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute of Arthritis and
Musculoskeletal and Skin Diseases;
Notice of Closed Meetings
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
VerDate Sep<11>2014
19:23 Feb 26, 2016
Jkt 238001
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meetings.
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Multisite Clinical Trials.
Date: March 10, 2016.
Time: 10:30 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Susan O. McGuire, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, National Institutes of Health,
DHHS, 6001 Executive Blvd., Room 4245,
Rockville, MD 20852, 301–435–1426,
MCGUIRESO@MAIL.NIH.GOV.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Mechanism for Time-Sensitive Drug Abuse
Research (R21).
Date: March 11, 2016.
Time: 12:00 p.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Hiromi Ono, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, National Institutes of Health,
DHHS, 6001 Executive Boulevard, Room
4238, MSC 9550, Bethesda, MD 20892, 301–
402–6020, hiromi.ono@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; CuttingEdge Basic Research Awards (CEBRA) (R21).
Date: March 17, 2016.
Time: 9:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Susan O. McGuire, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, National Institutes of Health,
E:\FR\FM\29FEN1.SGM
29FEN1
]]>Agencies
[Federal Register Volume 81, Number 39 (Monday, February 29, 2016)]
[Notices]
[Page 10262]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-04236]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Arthritis and Musculoskeletal and Skin
Diseases; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and contract proposals
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Arthritis and Musculoskeletal and Skin
Diseases Initial Review Group; Arthritis and Musculoskeletal and
Skin Diseases Clinical Trials Review Committee; AMSC Clinical Review
Meeting.
Date: March 15-16, 2016.
Time: March 15, 2016, 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda Marriott Suites, 6711 Democracy Boulevard,
Bethesda, MD 20817.
Contact Person: Charles H. Washabaugh, Ph.D., Scientific Review
Officer, Scientific Review Branch NIAMS/NIH, 6701 Democracy
Boulevard, Suite 816, Bethesda, MD 20892, 301-594-4952,
washabac@mail.nih.gov.
Name of Committee: National Institute of Arthritis and
Musculoskeletal and Skin Diseases Special Emphasis Panel; Clinical
Studies Management.
Date: March 17, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health/NIAMS, One Democracy Plaza,
6701 Democracy Boulevard, Bethesda, MD 20892.
Contact Person: Kathy ScD Salaita, Chief, Scientific Review
Branch, Center for Scientific Review, National Institutes of Health,
6701 Rockledge Drive, Room 3172, MSC 7770, Bethesda, MD 20892, 301-
806-8250, salaitak@csr.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.846,
Arthritis, Musculoskeletal and Skin Diseases Research, National
Institutes of Health, HHS)
Dated: February 23, 2016.
Sylvia Neal,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-04236 Filed 2-26-16; 8:45 am]
BILLING CODE 4140-01-P
